Levosimendan improves event free survival by 50 percent in end-stage heart failure
Ambulatory levosimendan improves event free survival by 50% compared to placebo, according to results from the LevoRep Study presented today during the late breaking trial session1 of the Heart Failure Congress 2013. In a ...
May 27, 2013